JP2018522851A5 - - Google Patents

Info

Publication number

JP2018522851A5

JP2018522851A5 JP2017565208A JP2017565208A JP2018522851A5 JP 2018522851 A5 JP2018522851 A5 JP 2018522851A5 JP 2017565208 A JP2017565208 A JP 2017565208A JP 2017565208 A JP2017565208 A JP 2017565208A JP 2018522851 A5 JP2018522851 A5 JP 2018522851A5

Authority

JP

Japan

Prior art keywords

binding antagonist

medicament

composition

individual

taxane

Prior art date

2016-06-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000005557 antagonist Substances 0.000 claims 66
• 239000003814 drug Substances 0.000 claims 62
• 239000000203 mixture Substances 0.000 claims 47
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical group O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 43
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 38
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 38
• 229940123237 Taxane Drugs 0.000 claims 31
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 29
• 229960001592 paclitaxel Drugs 0.000 claims 28
• 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 26
• 229940028652 abraxane Drugs 0.000 claims 26
• 108010074708 B7-H1 Antigen Proteins 0.000 claims 25
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 25
• 238000011282 treatment Methods 0.000 claims 24
• 206010055113 Breast cancer metastatic Diseases 0.000 claims 21
• 206010006187 Breast cancer Diseases 0.000 claims 17
• 229960003852 atezolizumab Drugs 0.000 claims 17
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims 15
• 239000003937 drug carrier Substances 0.000 claims 12
• 230000008878 coupling Effects 0.000 claims 8
• 238000010168 coupling process Methods 0.000 claims 8
• 238000005859 coupling reaction Methods 0.000 claims 8
• 230000004044 response Effects 0.000 claims 6
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 5
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 5
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 5
• 210000001744 T-lymphocyte Anatomy 0.000 claims 5
• 230000003442 weekly effect Effects 0.000 claims 4
• 238000000034 method Methods 0.000 claims 3
• 229930012538 Paclitaxel Natural products 0.000 claims 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 231100000433 cytotoxic Toxicity 0.000 claims 2
• 230000001472 cytotoxic effect Effects 0.000 claims 2
• 229940079593 drug Drugs 0.000 claims 2
• 229950009791 durvalumab Drugs 0.000 claims 2
• 230000002708 enhancing effect Effects 0.000 claims 2
• 230000036737 immune function Effects 0.000 claims 2
• 238000003364 immunohistochemistry Methods 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 229960003301 nivolumab Drugs 0.000 claims 2
• 230000009885 systemic effect Effects 0.000 claims 2
• 238000002560 therapeutic procedure Methods 0.000 claims 2
• 238000011269 treatment regimen Methods 0.000 claims 2
• 208000026310 Breast neoplasm Diseases 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 230000004913 activation Effects 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 238000003556 assay Methods 0.000 claims 1
• 230000003796 beauty Effects 0.000 claims 1
• 235000021152 breakfast Nutrition 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 210000004027 cell Anatomy 0.000 claims 1
• 238000011260 co-administration Methods 0.000 claims 1
• 230000001461 cytolytic effect Effects 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 239000003446 ligand Substances 0.000 claims 1
• 230000001394 metastastic effect Effects 0.000 claims 1
• 206010061289 metastatic neoplasm Diseases 0.000 claims 1
• -1 optionally Proteins 0.000 claims 1
• 229960002621 pembrolizumab Drugs 0.000 claims 1
• 230000037452 priming Effects 0.000 claims 1
• 230000035755 proliferation Effects 0.000 claims 1
• 229950007213 spartalizumab Drugs 0.000 claims 1
• 239000000126 substance Substances 0.000 claims 1
• 230000002459 sustained effect Effects 0.000 claims 1
• 238000002054 transplantation Methods 0.000 claims 1